Nurix Therapeutics Gains 86% Upside Potential After $2.3B Roche BTK Deal
NRIX•Analysts raised Nurix’s price target to $34, implying an 86% upside from recent levels. The company secured up to $2.3 billion from Roche for its BTK degrader bexobrutideg, including a $700 million upfront payment and shared U.S. development costs and profits.
1. Partnership Structure
Nurix entered a collaboration with Roche valued at up to $2.3 billion for its BTK-degrading drug bexobrutideg. The agreement features a $700 million upfront payment, a 60/40 split of development costs and a 50/50 profit-and-loss sharing arrangement in the United States.
2. Price Target Revision
Analysts lifted the price target for Nurix to $34, reflecting an 86% upside from the $15.89 trading level at announcement. This revision underscores confidence in the commercial prospects of bexobrutideg and the strength of the Roche partnership.
3. Trading and Sentiment
Shares surged about 7% to $15.66 on volume exceeding 15.4 million, outperforming the 50-day moving average. Short interest stands near 19.8% of the float, suggesting potential for additional buying pressure if sentiment continues to improve.
